This morning Allergy Therapeutics has announced it has completed patient enrolment for its Phase IIb dose-finding study, G204, in the US. GrassMATAMPL is the company's programme for Pollinex Quattro Grass in the US (an ultra-short course SCIT, subcutaneous allergen specific immunotherapy) and total patient enrolment for the Phase IIb study was 250 patients. Headline data for the G204 study are expected at the end of the first half of 2016, paving the way for the US Phase III study.
